TrialPath
★ Glioblastoma

Glioblastoma clinical trials — recruiting now

There are 20+ glioblastoma studies currently recruiting participants across the US. Every eligibility criterion translated into plain English.

Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma

NCT07364786 · Glioblastoma
Recruiting

The objective of this clinical trial is to investigate the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, in participants undergoing diagnostic biopsies for suspected glioblastoma. The primary questions the trial seeks to answer are: * Will Salovum® reduce intratumoral pressure? * Will Salovum® influence the release of inflammatory cytokines from tumor tissue? Additionally, the study will investigate the impact of Salovum® on intratumoral partial oxygen pressure and tumor volume. Researchers will: * Place probes for measuring intratumoral pressure, microdialysis, and partial oxygen pressure during a standard biopsy procedure. * Compare measurements from participants before and during ingestion of Salovum®. Participants will: * Have probes implanted during a surgical biopsy. * Ingest Salovum® 24 to 72 hours after the procedure.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereLund, Sweden
SponsorPeter Siesjö
▾Tap for details
Apply

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

Recruiting

A single-center, open-label, non-randomized phase I/II study to evaluate the efficacy, safety and tolerance of crizanlizumab monotherapy and in combination with nivolumab in patients with advanced glioblastoma (GB) who exhausted standard of care (SOC) therapy, patients with metastatic brain melanoma (MBM) and patients with newly diagnosed unmethylated GB. Subjects will be screened for up to 28 days prior to treatment initiation. Eligible subjects will be allocated to one of 3 cohorts: Cohort 1: Patients with metastatic melanoma with primarily diagnosed or newly progressing brain metastases who failed immunotherapy. Cohort 2: Patients with recurrent or progressing GB following primary radiation therapy and temozolomide. Patients may have failed up to 2 prior systemic treatment lines (including temozolomide as adjuvant therapy) and are candidates for further treatment. Cohort 3: Patients with newly diagnosed GB who were evaluated for methylguanine-DNA methyltransferase(MGMT) methylation status and have un-methylated MGMT promotor-therefore, they are not candidates for maintenance temozolomide therapy.

PhasePhase 2
TypeInterventional
Age18 Years
WhereRamat Gan, Israel, Israel
SponsorSheba Medical Center
▾Tap for details
Apply

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

Recruiting

This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic profiles and preliminary clinical activity in participants with a high grade diffuse glioma that progressed during or recurred after prior standard of care therapies or investigational therapies as clinically indicated. Patients will be treated daily with GLIX1 capsules until disease progression or unacceptable safety.

PhasePhase 1
TypeInterventional
Age18 Years
WherePalo Alto, California, United States + 3 more
SponsorTetragon Biosciences Ltd
▾Tap for details

Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)

NCT07375992 · Glioblastoma (GBM)
Recruiting

The Brain Cancer Program, in partnership with the Center for Music and Medicine at Johns Hopkins, will study whether music therapy is feasible in newly diagnosed GBM patients undergoing standard care.

PhaseNA
TypeInterventional
Age18 Years
WhereBaltimore, Maryland, United States
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
▾Tap for details
Apply

BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors

NCT07485049 · Glioblastoma (GBM)
Recruiting

This is an open-label, multi-center, Phase 0/2 trial designed to enroll up to 78 total participants with suspected newly diagnosed glioblastoma (nGBM) who are scheduled for surgical resection to accrue at least 14 participants in Arm A and 10 participants in Arm B. The trial will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of BGB-58067. The study is composed of a Phase 0 and expansion Phase 2 component. The Phase 0 primary endpoint will be suppression of symmetric dimethylarginine (SDMA) in tumor tissue measured by immunohistochemistry (IHC). The Phase 2 primary endpoint will be 12-month overall survival rate (OS12). The Phase 0 secondary endpoint will be to characterize the PK of BGB-58067 in tumor tissue, plasma, and cerebrospinal fluid (CSF). The Phase 2 secondary endpoints will include assessing the safety profile of BGB-58067 and evaluating clinical efficacy of BGB 58067 using overall survival (OS) and the 6-month progression-free survival rate (PFS6) estimated by Kaplan-Meier (K-M) methods.

PhaseEARLY_Phase 1
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States
SponsorNader Sanai
▾Tap for details
Apply

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

Recruiting

This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In addition to the standard diagnostics of anatomic imaging and surgical histology, sonobiopsy has the potential to become the third pillar for brain tumor management by radically advancing the ability to easily and regularly acquire tumor genetic and molecular signatures. This enhanced capability will have a dramatic impact on patient survival and quality of life.

PhaseNA
TypeInterventional
Age18 Years
WhereSt Louis, Missouri, United States
SponsorWashington University School of Medicine
▾Tap for details
Apply

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

NCT06860594 · Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant
Recruiting

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving triapine in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.

PhasePhase 1
TypeInterventional
Age18 Years
WhereDuarte, California, United States + 42 more
SponsorNational Cancer Institute (NCI)
▾Tap for details

Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma

NCT05954858 · Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme
Recruiting

This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome (GBM) patients. The objective of the Phase 2 study is to demonstrate that this surgical technique is safe and effective in a human cohort of patients with resected newly diagnosed AA or GBM and may improve progression-free survival (PFS) and overall survival (OS).

PhaseNA
TypeInterventional
Age18 Years
WhereNew York, New York, United States
SponsorNorthwell Health
▾Tap for details
Apply

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

NCT04573140 · Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma
Recruiting

The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in (Stratum 1) adult patients with newly diagnosed GBM (MGMT low level or unmethylated in adults only) and (Stratum 2) in pediatric patients with newly diagnosed HGG (pHGG). Funding Source - FDA OOPD

PhasePhase 1
TypeInterventional
Age4 Years
WhereWashington D.C., District of Columbia, United States + 1 more
SponsorUniversity of Florida
▾Tap for details
Apply

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

Recruiting

The purpose of the study is to evaluate the safety and survival of carmustine wafers and radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult subjects with glioblastoma multiform after carmustine wafer placement.

PhasePhase 1
TypeInterventional
Age18 Years – 100 Years
WhereBaltimore, Maryland, United States
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
▾Tap for details
Apply

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

NCT02861898 · Glioblastoma, Brain Cancer, Brain Neoplasm
Recruiting

Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers remain a significant unmet clinical need in oncology. GBM often has a high expression EFGR (Epidermal Growth Factor Receptor) which is blocked by Cetuximab (CTX). The investigators have recently completed a separate Phase I clinical trial using superselective intra-arterial cerebral infusion (SIACI) of CTX after blood brain barrier disruption (BBBD) for recurrent GBM (Chakraborty et al, in revision, Journal of Neurooncology). The investigators found that intra-arterial infusion of CTX is well tolerated with few adverse effects. The investigators hypothesize that in patients with newly diagnosed GBM, repeated SIACI of this drug after BBBD will be safe and efficacious for our patients when combined with standard chemoradiation (STUPP protocol). This trial will be a non-randomized open label Phase I/II clinical trial. In addition to standard chemotherapy and radiation therapy (STUPP protocol) the patient will be given CTX intra-arterially after BBBD for a total of three doses at approximately post surgery days 30, 120 and 210.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereNew York, New York, United States
SponsorNorthwell Health
▾Tap for details
Apply

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

NCT07493447 · Meningioma, Glioblastoma, Acoustic Neuroma
Recruiting

This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.

PhaseEARLY_Phase 1
TypeInterventional
Age18 Years
WhereNashville, Tennessee, United States
SponsorEben Rosenthal
▾Tap for details
Apply

Clinical Study of Oncolytic Virus in Glioblastoma

NCT07145047 · Glioblastoma (GBM)
Recruiting

This clinical trial aims to evaluate whether an oncolytic viral agent can treat recurrent glioblastoma. It will also assess the safety and tolerability of the oncolytic viral agent. The primary question it seeks to answer is: What medical problems do participants experience when injected with the oncolytic viral agent? Researchers will administer the oncolytic viral agent via intratumoral injection to determine its efficacy in treating recurrent glioblastoma. Participant Procedures: Receive the initial injection, followed by additional injections every 2-4 weeks for a total of 6 injections. Undergo physical examinations and tests every 2 to 4 weeks. Record their symptoms, hematological test results, and imaging findings.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years – 70 Years
WhereMianyang, Sichuan, China
SponsorMianyang Central Hospital
▾Tap for details
Apply

Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07733674 · Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Recruiting

The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: How does 203Pb-RMX-VH-PIB spread in the body (biodistribution)? What is the radiation dose delivered to organs (dosimetry)? Participants will: Receive a single intravenous (IV) injection of 203Pb-RMX-VH-PIB. Undergo multiple single-photon emission computed tomography/computed tomography (SPECT/CT) imaging scans. Have blood, urine, vital signs, and electrocardiogram (ECG) monitored for safety. Be followed for any side effects for up to 30 days.

PhasePhase 1
TypeInterventional
Age18 Years
WhereHouston, Texas, United States
SponsorRadiomedix, Inc.
▾Tap for details
Apply

A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma

NCT07579208 · Phase 1, NK Cell, IL13Ra
Recruiting

To find the best method of administering NK cells in patients with recurrent glioblastoma.

PhasePhase 1
TypeInterventional
Age18 Years
WhereHouston, Texas, United States
SponsorM.D. Anderson Cancer Center
▾Tap for details
Apply

Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System for Intraoperative Balloon Electronic Brachytherapy

NCT07141732 · Glioblastoma
Recruiting

Glioblastoma is the most aggressive primary brain tumor due to its highly infiltrative growth pattern, strong proliferative potential, and multiple mechanisms of resistance to treatment . Based on results from multicenter studies, English oncologist Roger Stupp proposed in 2005 a new treatment approach involving initial tumor resection followed by conformal external beam radiation therapy combined with temozolomide, plus subsequent cycles of monochemotherapy with this drug. This approach extended median survival by only 2 months, yet remains the standard of care due to lack of better alternatives. Consequently, recent protocols for malignant CNS tumors in Russia and internationally recommend prioritizing clinical trial enrollment over "standard" treatment. Numerous studies demonstrate that the extent of resection of contrast-enhancing GB volume on MRI positively correlates with progression-free and overall survival. This is explained by the fact that adjuvant chemoradiation methods and the body's immune responses show efficacy only with small residual tumor volumes. The interval between surgery and adjuvant therapy negatively correlates with survival outcomes, potentially because the mitotic cycle of GB stem cells lasts only 24 hours. From this perspective, intraoperative radiation therapy (IORT) may improve treatment results. Attempts to use various IORT technologies for malignant brain gliomas span several decades. Some studies reported better survival with IORT compared to controls, but most involved small patient groups without reliable resection control or dosimetric assessment due to technological limitations. Early IORT methods used bulky linear accelerators producing high-energy electron beams. With portable systems, renewed interest emerged first in breast cancer, then neurosurgery. Neuroimaging and software now enable precise treatment planning. Bensaleh S. et al. evaluated balloon brachytherapy (MammoSite®) for early breast cancer in 2009. The device featured a dual-lumen catheter with a balloon inserted into the resection cavity. After contrast inflation and CT planning, 192Ir delivered 34 Gy in 10 fractions over 5 days to 1 cm depth. While comparable to conventional radiotherapy in 3-5 year survival, the 16% infection rate from prolonged implantation was a major drawback. A case report described using a similar breast cancer system (Contura balloon applicator) for recurrent malignant glioma in a 47-year-old patient. A single 20 Gy fraction showed no complications at 6-month follow-up. The Zeiss INTRABEAM system uses a miniature 50 kV linear accelerator with rigid spherical applicators producing low-energy x-rays for high surface doses with limited penetration. The 2018 INTRAGO phase I/II trial by Giordano et al. evaluated dose escalation (20→40 Gy) in 15 newly diagnosed GB patients. No complications (wound healing issues, bleeding, ischemia, or radionecrosis requiring surgery) occurred. Median PFS was 17.7 months (95% CI 9.7-25.9) in protocol-compliant patients, with distant progression remaining challenging. A recent advancement is electronic brachytherapy using the Xoft Axxent eBx System, combining a 50 kV x-ray source with a silicone balloon applicator conforming to resection cavities. Initially successful in breast and gynecologic cancers, its application expanded to neuro-oncology. In 2016, the European Medical Center (EMC) initiated a pilot study using Axxent eBx for recurrent GB post-standard chemoradiation. Twenty-nine patients received 20 Gy to the balloon surface after maximal safe resection. Median OS was 28.7 months (range 14-104) from first surgery. In patients with ≤2.5 cm³ residual tumor (n=16), median local PFS was 14.5 months (8-94), with 6- and 12-month PFS rates of 68.9% and 31% respectively. One grade 3 radionecrosis case occurred (CTCAE), with no infections or CSF leaks. Study Rationale: * Demonstrated survival benefits with gross-total resection of contrast-enhancing tumor * Negative survival impact of delayed adjuvant therapy initiation * Promising preliminary results of resection plus electronic brachytherapy in recurrent GB from EMC research This is a pilot, prospective, single-center, non-comparative study. Patients (N=15) with newly diagnosed glioblastoma will undergo intraoperative balloon-based electronic brachytherapy (IOBT) using the Xoft® Axxent® eBx® System immediately following gross total resection of the contrast-enhancing tumor. A single fractional dose of 20 Gy will be delivered to the balloon surface. Subsequently, patients will receive standard chemoradiotherapy according to the Stupp protocol (2005): * Concurrent phase (initiated 2-4 weeks postoperatively): * Radiotherapy: Conformal external beam radiation therapy (EBRT) to a total dose of 60 Gy (2 Gy/fraction over 6 weeks). * Chemotherapy: Daily oral temozolomide (75 mg/m²) during EBRT. * Adjuvant phase: * Monotherapy: 6-12 cycles (6-12 months) of adjuvant temozolomide (150-200 mg/m², days 1-5 of each 2

PhasePhase 1
TypeInterventional
Age40 Years – 75 Years
WhereMoscow, Moscow, Russia
SponsorJoint Stock Company European Medical Centre
▾Tap for details
Apply

Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 Trial

Recruiting

This clinical trial studies how well advanced imaging-guided standard dose versus (vs.) dose-intensified radiation therapy (RT) and dose-intensified accelerated RT works in treating patients with newly diagnosed glioblastoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. During dose-intensified RT, a higher dose than normal of radiation therapy is delivered over 6 weeks. During dose-intensified accelerated RT, the higher dose of radiation therapy is delivered over a shorter amount of time (2 weeks) than normal (6 weeks). Patients also undergo an advanced brain imaging positron emission tomography (PET)/computed tomography (CT) scan (using a radioactive drug called either FET or FDOPA) prior to RT to that may help doctors better plan the treatment. Dose-intensified and dose-intensified accelerated radiation therapy may be effective in treating patients with newly diagnosed glioblastoma. Giving dose-intensified RT or dose-intensified accelerated RT guided by advanced imaging may work better than standard dose RT in treating patients with newly diagnosed glioblastoma. IND Numbers: 61300, 140882, 176402, 154793, 167879

PhasePhase 3
TypeInterventional
Age18 Years
WhereScottsdale, Arizona, United States + 7 more
SponsorMayo Clinic
▾Tap for details
Apply

Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma

Recruiting

A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and glioblastoma. Safety, tolerability, and biodistribution characteristics of 68Ga-XT771 will also be assessed.

PhaseEARLY_Phase 1
TypeInterventional
Age18 Years
WhereBeijing, China
SponsorChinese PLA General Hospital
▾Tap for details
Apply

Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression

NCT05565118 · High Grade Glioma, Glioblastoma
Recruiting

The purpose of this study is to test the safety and feasibility of recording brain activity within and around high-grade glioma tumors at the time of surgery. A small biopsy will be taken at the sites of the recordings.

PhasePhase 1
TypeInterventional
Age18 Years
WhereCleveland, Ohio, United States
SponsorCase Comprehensive Cancer Center
▾Tap for details
Apply

OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial

NCT06558214 · Recurrent Glioblastoma
Recruiting

In this study we are evaluating the safety and feasibility of the triple combination (TTFields, MLA, pembrolizumab) in adult patients diagnosed with recurrent or progressive glioblastoma (GBM) WHO Grade IV, IDH wild type or recurrent or progressive astrocytoma WHO grade IV.

PhasePhase 2
TypeInterventional
Age18 Years – 90 Years
WhereGainesville, Florida, United States
SponsorUniversity of Florida
▾Tap for details
Apply